New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to...
“We identified a subset of brain tumor cells that are slower growing or remain at rest, and appear to be the source of cancer recurrence after standard therapy in which the drug temozolomide is given to stop the tumor’s growth,” said Dr. Luis Parada. “Current therapy targets fast-growing tumor cells but not those responsible for new tumors. To the best of our knowledge, this is the first identification of a cancer stem-like cell in a spontaneously forming tumor inside a mammal.”
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Scientists have long believed that glioblastoma multiforme, the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. Researchers found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons.
In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and glioblastoma multiforme tumors.
A new study discovers molecular pathways that could lead to new targeted therapies which may potentially treat Glioblastoma, the most common and lethal form of brain cancer in adults.
A new drug could help increase the effectiveness of radiation therapy for patients with glioblastoma multiforme, the most deadly form of brain cancer. The ATM kinase inhibitor, in combination with radiation therapy, helped significantly extend survival rates in mouse models of GBM.
Researchers have developed a new approach for treating glioblastoma brain cancer. The findings are shown to extend the life of animals treated for the cancer.
Researchers discover a way to adjust the malignancy of glioma brain cancer cells in a newly developed 3D hydrogel. The new material mimics the conditions in the brain.
Researchers delve deeply into the genomics of 599 GBM brain cancer cases to better target the disease.
A novel therapeutic, which is based on nanotechnology, turns off a critical gene and increases survival rates in mice with glioblastoma brain cancer, a new study reports.
Brain cancer cells resist therapy by temporarily losing gene mutations targeted by drugs, but re-amplify the mutation once the treatments have stopped, a new study reports.
